Edition:
India

Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

3.94USD
10:07pm IST
Change (% chg)

$-0.07 (-1.75%)
Prev Close
$4.01
Open
$4.03
Day's High
$4.05
Day's Low
$3.87
Volume
15,707
Avg. Vol
69,089
52-wk High
$6.70
52-wk Low
$3.20

Chart for

About

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth... (more)

Overall

Beta: 2.37
Market Cap(Mil.): $221.93
Shares Outstanding(Mil.): 50.55
Dividend: --
Yield (%): --

Financials

BRIEF-Cascadian Therapeutics reports Q3 loss per share $0.28

* Cascadian Therapeutics reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Cascadian Therapeutics announces FDA orphan drug designation granted to Tucatinib for the treatment of HER2 colorectal cancer

* Cascadian Therapeutics announces FDA orphan drug designation granted to tucatinib for the treatment of HER2+ metastatic colorectal cancer Source text for Eikon: Further company coverage:

27 Sep 2017

BRIEF-Cascadian Therapeutics Q2 loss per share $0.30

* Cascadian Therapeutics reports second quarter 2017 financial results

09 Aug 2017

BRIEF-Cascadian Therapeutics announces positive regulatory update for Tucatinib in Europe

* Cascadian Therapeutics announces positive regulatory update for tucatinib in Europe

11 Jul 2017

BRIEF-Cascadian Therapeutics’ tucatinib, receives orphan drug designation from FDA

* Cascadian therapeutics' lead candidate, tucatinib, receives orphan drug designation from fda for treatment of breast cancer patients with brain metastases‍​ Source text for Eikon: Further company coverage:

08 Jun 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF244.80 +14.70
Roche Holding Ltd. (RO.S) CHF245.50 +12.20
GlaxoSmithKline plc (GSK.L) 1,313.00 +5.00
Eli Lilly and Co (LLY.N) $83.01 +0.12
Transgene SA (TRNG.PA) €2.66 -0.03
Puma Biotechnology Inc (PBYI.OQ) $104.50 -1.00

Earnings vs. Estimates